← Upstream Bio, Inc. (UPB) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Upstream Bio, Inc. (UPB)
Pharmaceutical Preparations · market cap $285M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
2
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Upstream Bio (UPB) is a small-cap clinical-stage pharma with 52 employees and a $428M market cap, built around a single asset: verekitug (UPB-101), currently in Phase 2 for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Severe Asthma. The company reported $96.7M in cash against a burn rate implying roughly 6 months of runway, creating an acute near-term financing imperative.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2026-12-01 (est.)Conferenceimp 2/10
- 2027-09-15 (est.)Phase 2 · Verekitugimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Verekitug (UPB-101) | Phase 2 | Chronic Rhinosinusitis With Nasal Polyps |
| Verekitug | Phase 2 | Severe Asthma |
Price & technical context
3-month
-32.9%
6-month
-45.9%
12-month
-73.2%
52-wk range
$5.04–$32.60
vs 50-day MA
-19.8%
vs 200-day MA
-57.8%
Realized vol
99.4%
Max drawdown
-84.5%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for UPB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.